Results: Our analysis, based on three large datasets, showed that GAS5 was significantly upregulated mainly in cholangiocarcinoma (CHOL), kidney renal clear cell carcinoma (KIRC), and liver hepatocellular carcinoma (LIHC) (p < 0.05). The gene discussed is GAS5; the disease is cholangiocarcinoma.